20-F/A: Bon Natural Life Limited Files Amended 20-F Report, Addressing Nasdaq Compliance

Bon Natural Life Limited amends its annual report on Form 20-F to include information on compliance with home country practices in lieu of certain Nasdaq listing rules.

Summary

• Bon Natural Life Limited has filed an amendment to its annual report on Form 20-F.
• The amendment includes information regarding the company's compliance with home country practices as an alternative to certain Nasdaq listing rules, specifically under Nasdaq Rule 5615(a)(3)(B)(i).
• The original filing was made on February 10, 2023, and amended on May 15, 2023.
• The amendment does not modify or update the disclosures presented in the original filing or its first amendment, and continues to speak as of the date of the original filing.
• The document emphasizes that it does not reflect events occurring after the filing of the Original Filing.
• The company is a Cayman Islands holding company that conducts all of its operations and operates its business in China through its PRC subsidiaries.
• As of September 30, 2022, the company had cash on hand of $840,861.
• The company had outstanding bank loans of approximately $4.8 million from several PRC banks as of September 30, 2022.
• The company closed a private offering of ordinary shares and warrants on January 17, 2023, raising $2,200,000.
• The company plans to fully implement remedial measures to address material weaknesses in internal control over financial reporting prior to December 31, 2023.

Sentiment

Score: 5

Explanation: The document is primarily a compliance update, with both positive aspects (efforts to address Nasdaq compliance, recent capital raise) and negative aspects (material weaknesses in internal control). The sentiment is neutral overall.

Positives

• The company is taking steps to address compliance with Nasdaq listing rules.
• The company has secured additional funding through a private offering, increasing its financial resources.
• The company is implementing remedial measures to improve internal control over financial reporting.

Negatives

• The company's disclosure controls and procedures were not effective as of September 30, 2022, due to material weaknesses in internal control over financial reporting.
• The company has unpaid tax liabilities of approximately $1.2 million as of September 30, 2022.
• The company is still working to remediate material weaknesses in internal control over financial reporting.

Risks

• The company's business is subject to complex and rapidly evolving laws and regulations in China.
• The Chinese government may exercise significant oversight and discretion over the conduct of the company's business.
• The company may face increased competition from new and existing firms with greater capital resources.
• The company's ability to execute on its business plan may be impaired if it does not obtain substantial additional financing.
• The company may face difficulties in protecting its intellectual property rights.
• The company may be classified as a PRC resident enterprise for PRC income tax purposes, which could result in unfavorable tax consequences.

Future Outlook

The company plans to fully implement remedial measures to address material weaknesses in internal control over financial reporting prior to December 31, 2023.

Industry Context

The announcement reflects the ongoing scrutiny and adjustments required for companies with operations in China to maintain compliance with both U.S. and Chinese regulations, particularly in areas of corporate governance and financial reporting.

Comparison to Industry Standards

• It's difficult to compare this announcement to industry standards as it is primarily a compliance update rather than a performance report.
• However, the company's efforts to address Nasdaq compliance and improve internal controls are generally expected of publicly listed companies, especially those with significant operations in jurisdictions with different regulatory environments.
• Comparable companies in the natural ingredients and health solutions industry, such as Chenguang Biotech and Koninklijke DSM N.V., also face similar compliance challenges and are expected to maintain robust corporate governance practices.

Stakeholder Impact

• Shareholders may be impacted by the company's efforts to address Nasdaq compliance and improve internal controls.
• The company's ability to execute on its business plan may be affected by its financial resources and regulatory environment.

Next Steps

• The company plans to fully implement remedial measures to address material weaknesses in internal control over financial reporting prior to December 31, 2023.

Key Dates

Keywords

compliance, Nasdaq, financial reporting, internal control, amendment, annual report, listing rules, financials, capital raise, China